Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer

@inproceedings{Nucera2011TargetingBW,
  title={Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer},
  author={Carmelo Nucera and Matthew A. Nehs and Sushruta S. Nagarkatti and Peter M. Sadow and Michal Mekel and Andrew H. Fischer and Paul S. Lin and Gideon E Bollag and Jack Lawler and Richard A. Hodin and Sareh Parangi},
  booktitle={The oncologist},
  year={2011}
}
PURPOSE B-Raf(V600E) may play a role in the progression from papillary thyroid cancer to anaplastic thyroid cancer (ATC). We tested the effects of a highly selective B-Raf(V600E) inhibitor, PLX4720, on proliferation, migration, and invasion both in human thyroid cancer cell lines (8505c(B-RafV600E) and TPC-1(RET/PTC-1 and wild-type B-Raf)) and in primary human normal thyroid (NT) follicular cells engineered with or without B-Raf(V600E). EXPERIMENTAL DESIGN Large-scale genotyping analysis by… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 46 CITATIONS

Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.

  • Translational research : the journal of laboratory and clinical medicine
  • 2014
VIEW 15 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Anaplastic Thyroid Carcinoma with Gastric Metastasis

  • Current health sciences journal
  • 2018
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.

  • Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • 2018